Medication monitoring for people with dementia in care homes: the feasibility and clinical impact of nurse-led monitoring

Sue Jordan, Marie Gabe, Louise Newson, Sherrill Snelgrove, Gerwyn Panes, Aldo Picek, Ian T Russell, Michael Dennis, Sue Jordan, Marie Gabe, Louise Newson, Sherrill Snelgrove, Gerwyn Panes, Aldo Picek, Ian T Russell, Michael Dennis

Abstract

Objectives: People with dementia are susceptible to adverse effects of medicines. However, they are not always closely monitored. We explored (1) feasibility and (2) clinical impact of nurse-led medication monitoring.

Design: Feasibility "before-and-after" intervention study.

Setting: Three care homes in Wales.

Participants: Eleven service users diagnosed with dementia, taking at least one antipsychotic, antidepressant, or antiepileptic medicine.

Intervention: West Wales Adverse Drug Reaction (ADR) Profile for Mental Health Medicines.

Outcome measures: (1) Feasibility: recruitment, retention, and implementation. (2) Clinical impact: previously undocumented problems identified and ameliorated, as recorded in participants' records before and after introduction of the profile, and one month later.

Results: Nurses recruited and retained 11 of 29 eligible service users. The profile took 20-25 minutes to implement, caused no harm, and supplemented usual care. Initially, the profile identified previously undocumented problems for all participants (mean 12.7 (SD 4.7)). One month later, some problems had been ameliorated (mean 4.9 (3.6)). Clinical gains included new prescriptions to manage pain (2 participants), psoriasis (1), Parkinsonian symptoms (1), rash (1), dose reduction of benzodiazepines (1), new care plans for oral hygiene, skin problems, and constipation.

Conclusions: Participants benefited from structured nurse-led medication monitoring. Clinical trials of our ADR Profile are feasible and necessary.

Figures

Figure 1
Figure 1
Participant flow diagram.

References

    1. National Patient Safety Agency (NPSA) Safety in Doses: Medication Safety Incidents in the NHS. London, UK: National Patient Safety Agency; 2007.
    1. HSC, (Health Service Commissioner for England) Care and Compassion? Report of the Health Service Ombudsman on ten investigations into NHS care of older people. Parliamentary and Health Service Ombudsman, The Stationery Office, London, UK, 2011, .
    1. Gabe M, Murphy F, Davies G, et al. Adverse events and nurse-led medication monitoring. Journal of Nursing Management. 2011;19(3):377–392.
    1. Jordan S. Adverse events: expecting too much of nurses and too little of nursing research. Journal of Nursing Management. 2011;19(3):287–292.
    1. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18, 820 patients. British Medical Journal. 2004;329(7456):15–19.
    1. Howard RL, Avery AJ, Slavenburg S, et al. Which drugs cause preventable admissions to hospital? A systematic review. British Journal of Clinical Pharmacology. 2007;63(2):136–147.
    1. International Conference on Harmonisation (ICH) ICH Harmonised Tripartite Guideline for Good Clinical Practice. Marlow, UK: Institute of Clinical Research; 1996.
    1. Forster AJ, Murff HJ, Peterson JF, Gandhi TK, Bates DW. Adverse drug events occurring following hospital discharge. Journal of General Internal Medicine. 2005;20(4):317–323.
    1. Gurwitz JH, Field TS, Judge J, et al. The incidence of adverse drug events in two large academic long-term care facilities. American Journal of Medicine. 2005;118(3):251–258.
    1. Gurwitz JH. Serious adverse drug effects—seeing the trees through the forest. The New England Journal of Medicine. 2006;354(13):1413–1415.
    1. Steinman MA, Handler SM, Gurwitz JH, Schiff GD, Covinsky KE. Beyond the prescription: medication monitoring and adverse drug events in older adults. Journal of the American Geriatrics Society. 2011;59(8):1513–1520.
    1. Brenner S, Detz A, López A, et al. Signal and noise: applying a laboratory trigger tool to identify adverse drug events among primary care patients. BMJ Quality and Safety. 2012;21(8):670–675.
    1. Alldred DP, Raynor DK, Hughes C, et al. Interventions to optimise prescribing for older people in care homes. Cochrane Database of Systematic Reviews. 2013;(2)CD009095
    1. Banerjee S. The use of antipsychotic medication for people with dementia: time for action. A report for the Minister of State for Care Services. An Independent|Report commissioned for the Department of Health, London, UK. 2009.
    1. Guthrie B, McCowan C, Davey P, Simpson CR, Dreischulte T, Barnett K. High risk prescribing in primary care patients particularly vulnerable to adverse drug events: cross sectional population database analysis in Scottish general practice. British Medical Journal. 2011;342d3514
    1. Testad I, Auer S, Mittelman M, et al. Nursing home structure and association with agitation and use of psychotropic drugs in nursing home residents in three countries: Norway, Austria and England. International Journal of Geriatric Psychiatry. 2010;25(7):725–731.
    1. Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer’s disease. Cochrane Database of Systematic Reviews. 2006;(1)CD003476
    1. Ballard C, Lana MM, Theodoulou M, et al. A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (The DART-AD Trial) PLoS Medicine. 2008;5(4, article e76)
    1. Sultzer DL, Davis SM, Tariot PN, et al. Clinical symptom responses to atypical antipsychotic medications in Alzheimer’s disease: phase 1 outcomes from the CATIE-AD effectiveness trial. American Journal of Psychiatry. 2008;165(7):844–854.
    1. Katz I, de Deyn P-P, Mintzer J, Greenspan A, Zhu Y, Brodaty H. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer’s disease and mixed dementia: a metal-analysis of 4 placebo-controlled clinical trials. International Journal of Geriatric Psychiatry. 2007;22(5):475–484.
    1. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. Journal of the American Medical Association. 2005;294(15):1934–1943.
    1. Ballard C, Hanney ML, Theodoulou M, et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. The Lancet Neurology. 2009;8(2):151–157.
    1. Smith TGH. Antipsychotics in dementia-mortality risks and strategies to reduce prescribing. Evidence-Based Mental Health. 2011;14(2):35–36.
    1. Vigen CLP, Mack WJ, Keefe RSE, et al. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer’s disease: outcomes from CATIE-AD. American Journal of Psychiatry. 2011;168(8):831–839.
    1. French DD, Campbell R, Spehar A, Cunningham F, Foulis P. Outpatient medications and hip fractures in the US: a national veterans study. Drugs and Aging. 2005;22(10):877–885.
    1. Pratt N, Roughead EE, Ramsay E, Salter A, Ryan P. Risk of hospitalization for hip fracture and pneumonia associated with antipsychotic prescribing in the elderly: a self-controlled case-series analysis in an Australian health care claims database. Drug Safety. 2011;34(7):567–575.
    1. Jalbert JJ, Daiello LA, Eaton CB, et al. Antipsychotic use and the risk of diabetes in nursing home residents with dementia. American Journal of Geriatric Pharmacotherapy. 2011;9(3):153–163.
    1. Iyer S, Naganathan V, McLachlan AJ, Le Couteur DG. Medication withdrawal trials in people aged 65 years and older: a systematic review. Drugs and Aging. 2008;25(12):1021–1031.
    1. Devanand DP, Pelton GH, Cunqueiro K, Sackeim HA, Marder K. A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer’s disease. International Journal of Geriatric Psychiatry. 2011;26(9):937–943.
    1. Declercq T, Petrovic M, Stichele RV, De Sutter AIM, Van Driel ML, Christiaens T. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and neuropsychiatric symptoms in elderly patients with dementia. Cochrane Database of Systematic Reviews. 2009;(3)CD007726
    1. Nelson JC, Devanand DP. A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia. Journal of the American Geriatrics Society. 2011;59(4):577–585.
    1. Banerjee S, Hellier J, Romeo R, et al. Study of the use of antidepressants for depression in dementia: the HTA-SADD trial—a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine. Health Technology Assessment. 2013;17(7):1–166.
    1. Romeo R, Knapp M, Hellier J, et al. Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. British Journal of Psychiatry. 2013;202:121–128.
    1. Harris T, Carey IM, Shah SM, DeWilde S, Cook DG. Antidepressant prescribing in older primary care patients in community and care home settings in England and Wales. Journal of the American Medical Directors Association. 2012;13(1):41–47.
    1. Jureidini J, Tonkin A. Overuse of antidepressant drugs for the treatment of depression. CNS Drugs. 2006;20(8):623–632.
    1. Coupland CA, Dhiman P, Barton G, et al. A study of the safety and harms of antidepressant drugs for older people: a cohort study using a large primary care database. Health Technology Assessment. 2011;15(28):1–202.
    1. Lewis JD, Stom BL, Localio AR, et al. Moderate and high affinity serotonin reuptake inhibitors increase the risk of upper gastrointestinal toxicity. Pharmacoepidemiology and Drug Safety. 2008;17(4):328–335.
    1. Healy D, Herxheimer A, Menkes DB. Antidepressants and violence: problems at the interface of medicine and law. PLoS Medicine. 2006;3(9)e372
    1. Masud T, Frost M, Ryg J, et al. Central nervous system medications and falls risk in men aged 60–75 years: the Study on Male Osteoporosis and Aging (SOMA) Age Ageing. 2013;42(1):121–124.
    1. Rabenda V, Bruyère O, Reginster JY. Risk of nonvertebral fractures among elderly postmenopausal women using antidepressants. Bone. 2012;51(4):674–679.
    1. Jordan S. Managing adverse drug reactions: an orphan task. Journal of Advanced Nursing. 2002;38(5):437–448.
    1. Jordan S, Tunnicliffe C, Sykes A. Minimizing side-effects: the clinical impact of nurse-administered “side-effect” checklists. Journal of Advanced Nursing. 2002;37(2):155–165.
    1. Stefan H. Epilepsy in the elderly: facts and challenges. Acta Neurologica Scandinavica. 2011;124(4):223–237.
    1. Andrew T, Milinis K, Baker G, Wieshmann U. Self reported adverse effects of mono and polytherapy for epilepsy. Seizure. 2012;21(8):610–613.
    1. Bootsma HP, Ricker L, Hekster YA, et al. The impact of side effects on long-term retention in three new antiepileptic drugs. Seizure. 2009;18(5):327–331.
    1. Uijl SG, Uiterwaal CSMP, Aldenkamp AP, et al. A cross-sectional study of subjective complaints in patients with epilepsy who seem to be well-controlled with anti-epileptic drugs. Seizure. 2006;15(4):242–248.
    1. Fossey J, Ballard C, Juszczak E, et al. Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial. British Medical Journal. 2006;332(7544):756–758.
    1. Alzheimer’s Society. Optimising treatment and care for behavioural and psychological symptoms of dementia: a Best Practice Guide, London, Alzheimer’s Society. 2011, .
    1. Wood-Mitchell A, James IA, Waterworth A, Swann A, Ballard C. Factors influencing the prescribing of medications by old age psychiatrists for behavioural and psychological symptoms of dementia: a qualitative study. Age and Ageing. 2008;37(5):547–552.
    1. McCleery J, Fox R. Antipsychotic prescribing in nursing homes. British Medical Journal. 2012;344(7848)e1093
    1. FDA. Information for Healthcare Professionals: Conventional Antipsychotics. 2008, .
    1. British National Formulary (BNF) British Medical Association and the Royal Pharmaceutical Society of Great Britain, London, UK. 2012, .
    1. NCC, (National Co-ordinating Council for Medication Error Reporting and Prevention. NCC MERP: The First Ten Years “Defining the Problem and Developing Solutions”. United States Pharmacopia, Rockville, Maryland. 2005, .
    1. Herxheimer A, Sanz E. Social, cultural and ethical aspects of drug use-changes over 40 years: a personal look back. European Journal of Clinical Pharmacology. 2008;64(2):107–114.
    1. Thompson A, Hetrick SE, Álvarez-Jiménez M, et al. Targeted intervention to improve monitoring of antipsychotic-induced weight gain and metabolic disturbance in first episode psychosis. Australian and New Zealand Journal of Psychiatry. 2011;45(9):740–748.
    1. Wightman R, Fielding J, Green S. Audit of antipsychotic prescribing in dementia: cambridgeshire results and lessons learnt. Psychiatria Danubina. 2011;23(1):S126–S129.
    1. Hill KD, Wee R. Psychotropic drug-induced falls in older people: a review of interventions aimed at reducing the problem. Drugs Aging. 2012;29(1):15–30.
    1. Cleary A, Walsh F, Connolly H, et al. Monitoring and documentation of side effects from depot antipsychotic medication: an interdisciplinary audit of practice in a regional mental health service. Journal of Psychiatric and Mental Health Nursing. 2012;19(5):395–401.
    1. Francis R. Report of the Mid Staffordshire NHS Foundation Trust Public Inquiry: Executive Summary. House of Commons, London, UK, The Stationery Office. 2013, .
    1. Jordan S, Hardy B, Coleman M. Medication management: an exploratory study into the role of community mental health nurses. Journal of Advanced Nursing. 1999;29(5):1068–1081.
    1. Jordan S, Knight J, Pointon D. Monitoring adverse drug reactions: scales, profiles, and checklists. International Nursing Review. 2004;51(4):208–221.
    1. Jordan S. The Prescription Drug Guide for Nurses. Maidenhead, UK: Open University Press, McGraw-Hill; 2008.
    1. Jordan S, Jones R, Sargeant MP. Adverse drug reactions: managing the risk. Journal of Nursing Management. 2009;17(2):175–184.
    1. Gabe ME, Jordan SE. Development and clinical gains of nurse-led medication profiles. Journal of Nursing Management. 2013
    1. Lancaster GA, Dodd S, Williamson PR. Design and analysis of pilot studies: recommendations for good practice. Journal of Evaluation in Clinical Practice. 2004;10:307–312.
    1. Arain M, Campbell MJ, Cooper CL, Lancaster GA. What is a pilot or feasibility study? A review of current practice and editorial policy. BMC Medical Research Methodology. 2010;10, article 67
    1. National Quality Forum. Patient Reported Outcomes (PROs) Workshop #1. Workshop Summary. 2012,
    1. Taylor D, Paton C, Kapur S. The Maudsley Prescribing Guidelines. 11th edition. Oxford, UK: Wiley Blackwell; 2012.
    1. Thabane L, Ma J, Chu R, et al. A tutorial on pilot studies: the what, why and how. BMC Medical Research Methodology. 2010;610(article 1)
    1. Robinson R. Some problems with clinical trials in elderly people. Gerontologia Clinica. 1961;3:247–257.
    1. Wilkin D, Thompson P. Crichton Royal Behavioural Rating Scale. User’s Guide to Dependency measures in Elderly People. Social Services Monographs. Sheffield, UK: University of Sheffield; 1999.
    1. Bowling A. Measuring Health: A Review of Quality of Life Measurement Scales. 3rd edition. OUP Maidenhead; 2005.
    1. Day JC, Wood G, Dewey M, Bentall RP. A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients. British Journal of Psychiatry. 1995;166:650–653.
    1. Talbot J, Keisu M, Stahle L. Clinical trials—collecting safety data and establishing the adverse drug reaction profile. In: Talbot J, Aronson JK, editors. Stephens’Detection and Evaluation of Adverse Drug Reactions: Principles and Practice. 6th edition. Chichester, UK: Wiley-Blackwell; 2012. pp. 215–289.
    1. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the beers criteria for potentially inappropriate medication use in older adults: results of a us consensus panel of experts. Archives of Internal Medicine. 2003;163(22):2716–2724.
    1. Zermansky AG, Alldred DP, Petty DR, Raynor DK. Striving to recruit: the difficulties of conducting clinical research on elderly care home residents. Journal of the Royal Society of Medicine. 2007;100(6):258–261.
    1. Barber ND, Alldred DP, Raynor DK, et al. Care homes’ use of medicines study: prevalence, causes and potential harm of medication errors in care homes for older people. Quality and Safety in Health Care. 2009;18(5):341–346.
    1. POMH Prescribing Observatory for Mental Health. Topic 2c Report 2c. Screening For Metabolic Side Effects of Antipsychotic Drugs in Patients Treated by Assertive Outreach Teams: Supplementary Audit. London, UK: The Royal College of Psychiatrists, College Centre for Quality Improvement; 2008.
    1. POMH Prescribing Observatory for Mental Health. Topic 6a. Assessment of the Side Effects of Depot Antipsychotics. London, UK: The Royal College of Psychiatrists, College Centre for Quality Improvement; 2008.
    1. Higgins JPT, Altman DG, Sterne JAC. Assessing risk of bias in included studies. In: Higgins JPT, editor. Cochrane Handbook for Systematic Reviews of Interventions Version 5. 1. 0. Cochrane Collaboration; 2011. .
    1. Sackett DL. Bias in analytic research. Journal of Chronic Diseases. 1979;32(1-2):51–68.
    1. Shanyinde M, Pickering RM, Weatherall M. Questions asked and answered in pilot and feasibility randomized controlled trials. BMC Medical Research Methodology. 2011;11, article 117
    1. Jordan S, Watkins A, Storey M, et al. Volunteer bias in recruitment, retention, and blood sample donation in a randomised controlled trial involving mothers and their children at six months and two years: a Longitudinal Analysis. PLoS ONE. 2013;8(7)e67912
    1. Groves RM. Nonresponse rates and nonresponse bias in household surveys. Public Opinion Quarterly. 2006;70(5):646–675.
    1. Council of International Organisations of Medical Sciences (CIOMS) International Ethical Guidelines for Biomedical Research Involving Human Subjects. Geneva, Switzerland, 2002, .
    1. Grol R. Improving the quality of medical care: building bridges among professional pride, payer profit, and patient satisfaction. Journal of the American Medical Association. 2001;286(20):2578–2585.
    1. Dückers M, Faber M, Cruijsberg J, Grol R, Schoonhoven L, Wensing M. Safety and risk management interventions in hospitals: a systematic review of the literature. Medical Care Research and Review. 2009;66(6, supplement):90S–119S.
    1. Lapane KL, Hughes CM, Daiello LA, Cameron KA, Feinberg J. Effect of a pharmacist-led multicomponent intervention focusing on the medication monitoring phase to prevent potential adverse drug events in nursing homes. Journal of the American Geriatrics Society. 2011;59(7):1238–1245.
    1. Arditi C, Rège-Walther M, Wyatt JC, et al. Computer-generated reminders delivered on paper to healthcare professionals, effects on professional practice and health care outcomes. Cochrane Database of Systematic Reviews. 2012;(12)CD001175
    1. Topinková E, Baeyens JP, Michel JP, et al. Evidence-based strategies for the optimization of pharmacotherapy in older people. Drugs Aging. 2012;29(6):477–494.
    1. Christensen M, Lundh A. Medication review in hospitalised patients to reduce morbidity and mortality. Cochrane Database of Systematic Reviews. 2013;282CD008986
    1. Proctor R, Burns A, Stratton Powell H, et al. Behavioural management in nursing and residential homes: a randomised controlled trial. The Lancet. 1999;354(9172):26–29.
    1. Spinewine A, Schmader KE, Barber N, et al. Appropriate prescribing in elderly people: how well can it be measured and optimised? The Lancet. 2007;370(9582):173–184.
    1. Bosboom PR, Alfonso H, Almeida OP, et al. Use of potentially harmful medications and health-related quality of life among people with dementia living in residential aged care facilities. Dementia and Geriatric Cognitive Disorders Extra. 2012;2(1):361–371.
    1. Zermansky AG, Alldred DP, Petty DR, et al. Clinical medication review by a pharmacist of elderly people living in care homes—randomised controlled trial. Age and Ageing. 2006;35(6):586–591.
    1. Gandhi TK, Weingart SN, Borus J, et al. Adverse drug events in ambulatory care. The New England Journal of Medicine. 2003;348(16):1556–1564.
    1. Tomlin A, Reith D, Dovey S, et al. Methods for retrospective detection of drug safety signals and adverse events in electronic general practice records. Drug Safety. 2012;35(9):733–743.
    1. Nguyen JK, Fouts MM, Kotabe SE, Lo E. Polypharmacy as a risk factor for adverse drug reactions in geriatric nursing home residents. American Journal Geriatric Pharmacotherapy. 2006;4(1):36–41.
    1. Office of the Inspector General. Prescription Drug use in nursing homes. In Report 2: An Inside View by Consultant Pharmacists. Dept. of Health and Human services Report No. OEI-06-96-00081. 1997, .
    1. Hazell L, Shakir SAW. Under-reporting of adverse drug reactions: a systematic review. Drug Safety. 2006;29(5):385–396.
    1. Olsen S, Neale G, Schwab K, et al. Hospital staff should use more than one method to detect adverse events and potential adverse events: incident reporting, pharmacist surveillance and local real-time record review may all have a place. Quality and Safety in Health Care. 2007;16(1):40–44.
    1. Miguel A, Marques B, Freitas A, et al. Detection of adverse drug reactions using hospital databases—a nationwide study in Portugal. Pharmacoepidemiology and Drug Safety. 2013;22(8):907–913.
    1. Heeley E, Riley J, Layton D, Wilton LV, Shakir SAW. Prescription-event monitoring and reporting of adverse drug reactions. The Lancet. 2001;358(9296):1872–1873.
    1. Nosè M, Mazzi MA, Esposito E, et al. Adverse effects of antipsychotic drugs: survey of doctors “versus patients” perspective. Social Psychiatry and Psychiatric Epidemiology. 2012;47(1):157–164.
    1. Glasziou P, Aronson JK. An introduction to monitoring therapeutic interventions in clinical practice. In: Glasziou P, Irwig L, Aronson JK, editors. Evidence Based Medical Monitoring. Oxford, UK: Blackwell Publishing/BMJ books; 2008. pp. 3–14.
    1. Shah SM, Carey IM, Harris T, et al. Quality of prescribing in care homes and the community in England and Wales. British Journal of General Practice. 2012;62(598):e329–e336.
    1. Montesi G, Lechi A. Prevention of medication errors: detection and audit. British Journal of Clinical Pharmacology. 2009;67(6):651–655.
    1. De Vries EN, Prins HA, Crolla RMPH, et al. Effect of a comprehensive surgical safety system on patient outcomes. The New England Journal of Medicine. 2010;363(20):1928–1937.
    1. Health Service Commissioner for England. Care and Compassion? Report of the Health Service Ombudsman on ten investigations into NHS care of older people. Parliamentary and Health Service Ombudsman, The Stationery Office, London, UK, 2011, .
    1. Schroll JB, Maund E, Gøtzsche PC. Challenges in coding adverse events in clinical trials: a systematic review. PLoS ONE. 2012;7(7)e41174
    1. Seale C, Chaplin R, Lelliott P, Quirk A. Antipsychotic medication, sedation and mental clouding: an observational study of psychiatric consultations. Social Science and Medicine. 2007;65(4):698–711.
    1. Quirk A, Chaplin R, Hamilton S, et al. Communication about adherence to long-term antipsychotic prescribing: an observational study of psychiatric practice. Social Psychiatry and Psychiatric Epidemiology. 2013;48(4):639–647.
    1. Review of Health and Social Care Burdens. Lifting the Burdens Task Force. London, UK: Local Government Association; 2008.
    1. Allen D, Hughes D. Expanded nursing roles: different occupational perspectives. In: Allen D, Hughes D, Jordan S, Prowse M, Snelgrove S, editors. Nursing and the Division of Labour in Healthcare. Basingstoke, UK: Palgrave MacMillan; 2002. pp. 99–128.
    1. Jordan S, Coleman M, Hardy B, Hughes D. Assessing educational effectiveness: the impact of a specialist course on the delivery of care. Journal of Advanced Nursing. 1999;30(4):796–807.
    1. Ginsburg LR, Chuang Y-T, Blair Berta W, et al. The relationship between organizational leadership for safety and learning from patient safety events. Health Services Research. 2010;45(3):607–632.
    1. Edwards N, Marshall M, McLellan A, Abbasi K. Doctors and managers: a problem without a solution? British Medical Journal. 2003;326(7390):609–610.
    1. McDonald R, Waring J, Harrison S, Walshe K, Boaden R. Rules and guidelines in clinical practice: a qualitative study in operating theatres of doctors’ and nurses’ views. Quality and Safety in Health Care. 2005;14(4):290–294.
    1. Caplan L, Haverhals LM. Barriers and facilitators for preventing adverse drug reactions of long latency: a qualitative study. The International Journal of Risk and Safety in Medicine. 2012;24(2):81–94.
    1. Mant D. A framework for developing and evaluating a monitoring strategy. In: Glasziou P, Irwig L, Aronson JK, editors. Evidence Based Medical Monitoring. Oxford, UK: Blackwell publishing/BMJ books; 2008. pp. 15–30.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi